ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?

ProQR Therapeutics (NASDAQ:PRQR)’s share price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $2.48 and traded as high as $2.63. ProQR Therapeutics shares last traded at $2.58, with a volume of 228,832 shares trading hands.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. JMP Securities restated a “market outperform” rating and set a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Oppenheimer initiated coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They set an “outperform” rating and a $15.00 price target on the stock. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $8.83.

ProQR Therapeutics Stock Up 6.6 %

The company’s 50 day simple moving average is $2.48 and its 200-day simple moving average is $2.61.

Institutional Trading of ProQR Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets increased its holdings in shares of ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 7,300 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of ProQR Therapeutics by 11.8% in the 4th quarter. Bank of America Corp DE now owns 81,784 shares of the biopharmaceutical company’s stock worth $217,000 after buying an additional 8,621 shares during the last quarter. Jane Street Group LLC bought a new position in shares of ProQR Therapeutics in the 4th quarter worth $30,000. Squarepoint Ops LLC increased its holdings in shares of ProQR Therapeutics by 16.3% in the 4th quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company’s stock worth $220,000 after buying an additional 11,623 shares during the last quarter. Finally, Invesco Ltd. bought a new position in shares of ProQR Therapeutics in the 4th quarter worth $32,000. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).